SCHEMBL313995

SCHEMBL313995

Cc1cccc(-c2nnc3n2-c2ccc(O)cc2NCC3)n1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 1/20 0.45
TGFBR1 P36897 4/20 0.34
MAPK14 Q16539 2/20 0.34
THRB P10828 1/20 0.34
CYP1A2 P05177 1/20 0.34
TACR3 P29371 1/20 0.34
CYP2C19 P33261 1/20 0.34
TNKS2 Q9H2K2 6/20 0.33
TNKS O95271 4/20 0.33
DRD2 P14416 1/20 0.33
DRD4 P21917 1/20 0.33
CCR1 P32246 1/20 0.33
CCR8 P51685 1/20 0.33
PDE2A O00408 1/20 0.31
PDE10A Q9Y233 1/20 0.31
MEN1 O00255 1/20 0.31
NPC1 O15118 1/20 0.31
POLB P06746 1/20 0.31
GAA P10253 1/20 0.31
RAB9A P51151 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL315206 0.87 BRD4 (0.45) BRD4TGFBR1MAPK14THRBCYP1A2
SCHEMBL314747 0.85 BRD4 (0.48) BRD4CYP1A2TACR3CYP2C19DRD2
SCHEMBL314194 0.85 BRD4 (0.44) BRD4TGFBR1MAPK14THRBAPLNR
SCHEMBL314814 0.81 BRD4 (0.46) BRD4DRD2DRD4PDE2APDE10A
SCHEMBL315096 0.81 TNKS2 (0.34) TGFBR1MAPK14THRBCYP1A2TACR3
SCHEMBL314758 0.78 TNKS2 (0.40) TGFBR1MAPK14THRBCYP1A2TACR3
SCHEMBL314350 0.78 TNKS2 (0.40) TGFBR1MAPK14THRBCYP1A2TACR3
SCHEMBL313824 0.78 TNKS2 (0.40) TGFBR1MAPK14THRBCYP1A2TACR3
SCHEMBL3403602 0.77 TNKS2 (0.35) BRD4TGFBR1MAPK14THRBCYP1A2
SCHEMBL313644 0.73 BRD4 (0.43) BRD4DRD2DRD4CYP17A1CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1966211-B1 TRIAZOLE DERIVATIVES MERCK PATENT GMBH (DE) 2012-12-26 EP claimed
US-8093240-B2 Triazole derivatives MERCK PATENT GMBH (DE) 2012-01-10 US claimed
EP-2322527-A1 Triazole derivatives Merck Patent GmbH (DE) 2011-05-18 EP claimed
US-20080306042-A1 Triazole Derivatives MERCK PATENT GMBH (DE) 2008-12-11 US claimed
EP-1966211-B1 TRIAZOLE DERIVATIVES MERCK PATENT GMBH (DE) 2012-12-26 EP disclosed
EP-1966211-B1 TRIAZOLE DERIVATIVES MERCK PATENT GMBH (DE) 2012-12-26 EP disclosed
US-8093240-B2 Triazole derivatives MERCK PATENT GMBH (DE) 2012-01-10 US disclosed
US-8093240-B2 Triazole derivatives MERCK PATENT GMBH (DE) 2012-01-10 US disclosed
US-8093240-B2 Triazole derivatives MERCK PATENT GMBH (DE) 2012-01-10 US disclosed
EP-2322527-A1 Triazole derivatives Merck Patent GmbH (DE) 2011-05-18 EP disclosed
EP-2322527-A1 Triazole derivatives Merck Patent GmbH (DE) 2011-05-18 EP disclosed
EP-2322527-A1 Triazole derivatives Merck Patent GmbH (DE) 2011-05-18 EP disclosed
US-20080306042-A1 Triazole Derivatives MERCK PATENT GMBH (DE) 2008-12-11 US disclosed
US-20080306042-A1 Triazole Derivatives MERCK PATENT GMBH (DE) 2008-12-11 US disclosed
US-20080306042-A1 Triazole Derivatives MERCK PATENT GMBH (DE) 2008-12-11 US disclosed
WO-2007079820-A1 TRIAZOLE DERIVATIVES MERCK PATENT GMBH (DE) 2007-07-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080306042-A1 Triazole Derivatives TGFBR1, TGFBR2, SMAD3 BRD4 808/4885TGFBR1 1/4885MAPK14 618/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.